CEO Kroeger Sells $5.44M in MapLight Stock Over Three Days
MPLT has more than doubled off its 52-week low of $12.24 on elevated volume (1.9× avg).
Summary
MapLight Therapeutics CEO Christopher Kroeger sold $5.44 million in stock between July 15-17, 2026, to cover tax obligations on vesting RSUs. The sales represent 0.34% of the company's market cap and come amid a challenging period for the biotech, including a recent Phase 2 trial miss and CFO departure.
Key Events · Ownership and Investor Activity · MPLT
-
CEO Sells $5.44M in Stock
Christopher Kroeger sold 147,639 shares at prices between $36.00 and $37.96, totaling $5.44 million, between July 15 and 17, 2026.
-
Tax-Driven but Large Disposal
The sales were mandated to cover tax withholding on vesting RSUs, but the amount represents 0.34% of the company's market cap, a significant reduction for a CEO.
-
Insider Selling Pattern Continues
This sale adds to a 90-day trend of insider distribution, with $17.8 million in open-market sales and no purchases, signaling a lack of insider buying conviction.
-
Challenging Company Backdrop
The sales follow a Phase 2 trial miss for ML-004 in June 2026 and the abrupt departure of the CFO in the same month, raising concerns about the company's outlook.
Analysis · MPLT · Life Sciences
Between July 15 and 17, CEO Christopher Kroeger sold $5.44 million worth of shares, marking a notable reduction in his direct holdings. Although the filing attributes these sales to tax withholding on vesting restricted stock units, the magnitude—0.34% of the company's market cap—is significant for a CEO, especially against a backdrop of recent clinical trial disappointment and a CFO departure. The trades were executed at prices near the current $37.87 level, suggesting no discount was needed. This is the first disclosure of these transactions, and they add to a pattern of insider selling over the past 90 days, with no open-market purchases by any insider during that period.
At the time of this filing, MPLT was trading at $37.87 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.6B. The 52-week trading range was $12.24 to $40.43. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.